Whitehawk Therapeutics, Inc. WHWK 深 滬
已收盤 02-06 16:00:00 美东时间
2.76
+0.050
+1.85%
華盛通- 最 高2.855
- 今 開2.71
- 成交量 10.63万股
- 最 低 2.63
- 昨 收 2.71
- 總市值 1.30亿
- 52周最高 3.7699
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 1.39
- 委 比 -98.02%
- 總股本 4712.84万
- 歷史最高 65.25
- 量 比 0.71
- 振 幅 8.30%
- 歷史最低 1.21
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Jones Trading Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $7
Jones Trading analyst Soumit Roy initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and announces Price Target of $7.
2025-12-23 02:19
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: W...
2025-12-01 21:00
Whitehawk Therapeutics Q3 EPS $(0.26) Misses $0.07 Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $0.07 by 488.06 percent. This is a 43.48 percent increase over losses of $(0.46) per
2025-11-06 21:37
Whitehawk Therapeutics Presents Data From Protein Tyrosine Kinase 7 Analysis From Over 157K Tumor Samples At 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments,
2025-10-25 00:34
美股牛股 | PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；生物技术股WHWK涨超24%
PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；WHWK涨超24%，与Tempus AI建立战略伙伴关系，共同推进肿瘤研究领域发展>>
2025-10-17 17:43
Tempus AI Enters A Multi-Year Collaboration With Whitehawk Therapeutics To Leverage Tempus' Real-World Data And AI Capabilities For Biomarker-Driven Cancer Research
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology
2025-10-16 20:32
Whitehawk Therapeutics Q2 EPS $(0.76) Misses $0.49 Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $0.49 by 254.16 percent. This is a 40.74 percent decrease over losses of $(0.54) per
2025-08-07 20:11
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
MORRISTOWN, N.J., June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to e...
2025-06-19 20:00
